View in EDS

Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer.

Saved in:
Bibliographic Details
Title: Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer.
Authors: Sakatani T; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Tanaka S; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Murakami K; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Jinno C; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Aguilar F; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Bresee C; Biostatistics Shared Resources, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Chan OTM; Clinical and Translational Research Program, University of Hawaii Cancer Center, Honolulu, HI, USA., Luthringer DJ; Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Contreras-Sanz A; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Black P; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Rosser CJ; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Nonagen Therapeutics Corp, Los Angeles, CA 90010, USA., Furuya H; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: hideki.furuya@cshs.org.
Source: Experimental and molecular pathology [Exp Mol Pathol] 2026 Jun; Vol. 146, pp. 105039. Date of Electronic Publication: 2026 Mar 16.
Publication Type: Journal Article; Validation Study
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0370711 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-0945 (Electronic) Linking ISSN: 00144800 NLM ISO Abbreviation: Exp Mol Pathol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41843975
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sakatani+T%22">Sakatani T</searchLink>; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.<br /><searchLink fieldCode="AU" term="%22Tanaka+S%22">Tanaka S</searchLink>; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.<br /><searchLink fieldCode="AU" term="%22Murakami+K%22">Murakami K</searchLink>; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.<br /><searchLink fieldCode="AU" term="%22Jinno+C%22">Jinno C</searchLink>; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.<br /><searchLink fieldCode="AU" term="%22Aguilar+F%22">Aguilar F</searchLink>; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.<br /><searchLink fieldCode="AU" term="%22Bresee+C%22">Bresee C</searchLink>; Biostatistics Shared Resources, Cedars-Sinai Medical Center, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Chan+OTM%22">Chan OTM</searchLink>; Clinical and Translational Research Program, University of Hawaii Cancer Center, Honolulu, HI, USA.<br /><searchLink fieldCode="AU" term="%22Luthringer+DJ%22">Luthringer DJ</searchLink>; Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Contreras-Sanz+A%22">Contreras-Sanz A</searchLink>; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.<br /><searchLink fieldCode="AU" term="%22Black+P%22">Black P</searchLink>; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.<br /><searchLink fieldCode="AU" term="%22Rosser+CJ%22">Rosser CJ</searchLink>; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Nonagen Therapeutics Corp, Los Angeles, CA 90010, USA.<br /><searchLink fieldCode="AU" term="%22Furuya+H%22">Furuya H</searchLink>; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: hideki.furuya@cshs.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220370711%22">Experimental and molecular pathology</searchLink> [Exp Mol Pathol] 2026 Jun; Vol. 146, pp. 105039. <i>Date of Electronic Publication: </i>2026 Mar 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Validation Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>0370711 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1096-0945 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200144800%22">00144800 </searchLink><i>NLM ISO Abbreviation: </i>Exp Mol Pathol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41843975
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.yexmp.2026.105039
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 105039
    Titles:
      – TitleFull: Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sakatani T
      – PersonEntity:
          Name:
            NameFull: Tanaka S
      – PersonEntity:
          Name:
            NameFull: Murakami K
      – PersonEntity:
          Name:
            NameFull: Jinno C
      – PersonEntity:
          Name:
            NameFull: Aguilar F
      – PersonEntity:
          Name:
            NameFull: Bresee C
      – PersonEntity:
          Name:
            NameFull: Chan OTM
      – PersonEntity:
          Name:
            NameFull: Luthringer DJ
      – PersonEntity:
          Name:
            NameFull: Contreras-Sanz A
      – PersonEntity:
          Name:
            NameFull: Black P
      – PersonEntity:
          Name:
            NameFull: Rosser CJ
      – PersonEntity:
          Name:
            NameFull: Furuya H
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2026 Jun
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1096-0945
          Numbering:
            – Type: volume
              Value: 146
          Titles:
            – TitleFull: Experimental and molecular pathology
              Type: main
ResultId 1